PARTNERING
Building better therapies for patients is at the heart of every partnership we form. We collaborate closely with our partners to pursue transformative therapeutic differentiation without compromise. Our AI-powered platform has been recognized as a critical enabler in best-in-class drug design and development, helping turn ambitious ideas into realities.
We collaborate with life science innovators around the globe, from multinational pharmaceutical companies and clinical-stage biotechs to early-stage startups and venture capitalists. By addressing real-world bottlenecks and de-risking critical stages of development, we co-create next-generation antibodies against challenging targets.
We take a results-driven approach—rooted in validated technologies and data-informed decision-making, delivering reliable antibody drug design in a competitive timeline.
For high-stakes, high-potential programs, i.e., “must-win” opportunities, we pursue multiple complementary strategies to increase the likelihood of success.
We leverage our deep, cross-functional expertise that spans the entire biologics discovery process, fostering partner's long-term success in an evolving therapeutic landscape.
Through a strategic platform-based collaboration, Lilly will gain access to Ailux’s AI-powered bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developability analytics to deliver therapeutic constructs with novel function, optimal efficacy and drug-like properties.
This agreement granted Janssen access to XtalFold, a proprietary AI-based software suite that provides rapid and accurate structural insights to accelerate biologics innovation across multiple phases.
“UCB have a strong legacy of antibody discovery and engineering. We have established unique and powerful single-B cell screening and in vitro display discovery technologies to support hit identification and are pioneers in structure-based and computer-aided optimisation of molecules. The XtalFold™ license takes this further, integrating antibody-antigen structural insights into the entire antibody discovery and optimisation workflow.”
Daniel Lightwood, Head of Antibody Discovery and Optimisation, UCB
“We have a running collaboration with Ailux on a novel immuno-oncology target. The entire team of Ailux engaged in our drug discovery program is very knowledgeable, experienced, and understanding. I would highly recommend Ailux for biologics drug discovery on novel targets.”
Chandan Seth Nanda, VP of Target & Drug Discovery, Pear Bio
Innovate together to build transformative medicines.
